54 results
8-K
EX-99.1
HGENQ
Humanigen, Inc
12 Apr 22
Regulation FD Disclosure
9:00am
treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry PREACH – M Trial Phase 2/3 for CMML: Recruitment Commenced
8-K
EX-99.1
HGENQ
Humanigen, Inc
2 Dec 21
Other Events
8:00am
in any c ountry LIVE - AIR ACTIV - 5 Recruitment sites 35 55 (Including 2 in S. Korea) Overall enrollment 520 up to 550 CRP<150 mg/L 351* 400* Inclusion
8-K
EX-99.1
szecxoc30lc
9 Nov 21
Regulation FD Disclosure
8:00am
8-K
EX-99.1
lxf3l9bs9lmf4
14 Sep 21
Regulation FD Disclosure
5:00pm
8-K
EX-10.1
25t6q8s9w
14 Jan 21
Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19
4:30pm
8-K
EX-99.1
hwaey59f on0
11 Jan 21
Regulation FD Disclosure
6:07am
424B3
etsz4l5n
12 Nov 20
Prospectus supplement
4:15pm
424B3
q1r21pkht cjhf
17 Aug 20
Prospectus supplement
8:45am
8-K
EX-99.1
kebuiyg klo
10 Aug 20
Regulation FD Disclosure
9:08am
424B3
6que8 fkapn56z131
5 Aug 20
Prospectus supplement
5:06pm